Cargando…

Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease

BACKGROUND: The TORRACTO(®) study evaluated the effects of tiotropium/olodaterol versus placebo on endurance time during constant work-rate cycling and constant speed shuttle walking in patients with chronic obstructive pulmonary disease (COPD) after 12 weeks of treatment. METHODS: The effects of on...

Descripción completa

Detalles Bibliográficos
Autores principales: Maltais, François, O’Donnell, Denis, Gáldiz Iturri, Juan Bautista, Kirsten, Anne-Marie, Singh, Dave, Hamilton, Alan, Tetzlaff, Kay, Zhao, Yihua, Casaburi, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937154/
https://www.ncbi.nlm.nih.gov/pubmed/29439648
http://dx.doi.org/10.1177/1753465818755091
_version_ 1783320581195694080
author Maltais, François
O’Donnell, Denis
Gáldiz Iturri, Juan Bautista
Kirsten, Anne-Marie
Singh, Dave
Hamilton, Alan
Tetzlaff, Kay
Zhao, Yihua
Casaburi, Richard
author_facet Maltais, François
O’Donnell, Denis
Gáldiz Iturri, Juan Bautista
Kirsten, Anne-Marie
Singh, Dave
Hamilton, Alan
Tetzlaff, Kay
Zhao, Yihua
Casaburi, Richard
author_sort Maltais, François
collection PubMed
description BACKGROUND: The TORRACTO(®) study evaluated the effects of tiotropium/olodaterol versus placebo on endurance time during constant work-rate cycling and constant speed shuttle walking in patients with chronic obstructive pulmonary disease (COPD) after 12 weeks of treatment. METHODS: The effects of once-daily tiotropium/olodaterol (2.5/5 and 5/5 μg) on endurance time during constant work-rate cycle ergometry (CWRCE) after 6 and 12 weeks of treatment were compared with placebo in patients with COPD in a randomized, double-blind, placebo-controlled, parallel-group clinical trial. Endurance time during the endurance shuttle walk test (ESWT) after 6 and 12 weeks of treatment was also evaluated in a subset of patients. RESULTS: A total of 404 patients received treatment, with 165 participating in the ESWT substudy. A statistically significant improvement in endurance time during CWRCE was observed after 12 weeks (primary endpoint) with tiotropium/olodaterol 5/5 µg [14% (p = 0.02)] but not with tiotropium/olodaterol 2.5/5 µg [9% (p = 0.14)] versus placebo. In the ESWT substudy, a trend to improvement in endurance time during ESWT after 12 weeks (key secondary endpoint) was observed with tiotropium/olodaterol 5/5 µg [21% (p = 0.055)] and tiotropium/olodaterol 2.5/5 µg [21% (p = 0.056)] versus placebo. CONCLUSION: Tiotropium/olodaterol 5/5 µg improved endurance time during cycle ergometry versus placebo, with a strong tendency to also improve walking endurance time. [ClinicalTrials.gov identifier: NCT01525615.]
format Online
Article
Text
id pubmed-5937154
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-59371542018-05-09 Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease Maltais, François O’Donnell, Denis Gáldiz Iturri, Juan Bautista Kirsten, Anne-Marie Singh, Dave Hamilton, Alan Tetzlaff, Kay Zhao, Yihua Casaburi, Richard Ther Adv Respir Dis Original Research BACKGROUND: The TORRACTO(®) study evaluated the effects of tiotropium/olodaterol versus placebo on endurance time during constant work-rate cycling and constant speed shuttle walking in patients with chronic obstructive pulmonary disease (COPD) after 12 weeks of treatment. METHODS: The effects of once-daily tiotropium/olodaterol (2.5/5 and 5/5 μg) on endurance time during constant work-rate cycle ergometry (CWRCE) after 6 and 12 weeks of treatment were compared with placebo in patients with COPD in a randomized, double-blind, placebo-controlled, parallel-group clinical trial. Endurance time during the endurance shuttle walk test (ESWT) after 6 and 12 weeks of treatment was also evaluated in a subset of patients. RESULTS: A total of 404 patients received treatment, with 165 participating in the ESWT substudy. A statistically significant improvement in endurance time during CWRCE was observed after 12 weeks (primary endpoint) with tiotropium/olodaterol 5/5 µg [14% (p = 0.02)] but not with tiotropium/olodaterol 2.5/5 µg [9% (p = 0.14)] versus placebo. In the ESWT substudy, a trend to improvement in endurance time during ESWT after 12 weeks (key secondary endpoint) was observed with tiotropium/olodaterol 5/5 µg [21% (p = 0.055)] and tiotropium/olodaterol 2.5/5 µg [21% (p = 0.056)] versus placebo. CONCLUSION: Tiotropium/olodaterol 5/5 µg improved endurance time during cycle ergometry versus placebo, with a strong tendency to also improve walking endurance time. [ClinicalTrials.gov identifier: NCT01525615.] SAGE Publications 2018-02-14 /pmc/articles/PMC5937154/ /pubmed/29439648 http://dx.doi.org/10.1177/1753465818755091 Text en © The Author(s), 2018 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Maltais, François
O’Donnell, Denis
Gáldiz Iturri, Juan Bautista
Kirsten, Anne-Marie
Singh, Dave
Hamilton, Alan
Tetzlaff, Kay
Zhao, Yihua
Casaburi, Richard
Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease
title Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease
title_full Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease
title_fullStr Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease
title_full_unstemmed Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease
title_short Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease
title_sort effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937154/
https://www.ncbi.nlm.nih.gov/pubmed/29439648
http://dx.doi.org/10.1177/1753465818755091
work_keys_str_mv AT maltaisfrancois effectof12weeksofoncedailytiotropiumolodaterolonexerciseenduranceduringconstantworkratecyclingandenduranceshuttlewalkinginchronicobstructivepulmonarydisease
AT odonnelldenis effectof12weeksofoncedailytiotropiumolodaterolonexerciseenduranceduringconstantworkratecyclingandenduranceshuttlewalkinginchronicobstructivepulmonarydisease
AT galdiziturrijuanbautista effectof12weeksofoncedailytiotropiumolodaterolonexerciseenduranceduringconstantworkratecyclingandenduranceshuttlewalkinginchronicobstructivepulmonarydisease
AT kirstenannemarie effectof12weeksofoncedailytiotropiumolodaterolonexerciseenduranceduringconstantworkratecyclingandenduranceshuttlewalkinginchronicobstructivepulmonarydisease
AT singhdave effectof12weeksofoncedailytiotropiumolodaterolonexerciseenduranceduringconstantworkratecyclingandenduranceshuttlewalkinginchronicobstructivepulmonarydisease
AT hamiltonalan effectof12weeksofoncedailytiotropiumolodaterolonexerciseenduranceduringconstantworkratecyclingandenduranceshuttlewalkinginchronicobstructivepulmonarydisease
AT tetzlaffkay effectof12weeksofoncedailytiotropiumolodaterolonexerciseenduranceduringconstantworkratecyclingandenduranceshuttlewalkinginchronicobstructivepulmonarydisease
AT zhaoyihua effectof12weeksofoncedailytiotropiumolodaterolonexerciseenduranceduringconstantworkratecyclingandenduranceshuttlewalkinginchronicobstructivepulmonarydisease
AT casaburirichard effectof12weeksofoncedailytiotropiumolodaterolonexerciseenduranceduringconstantworkratecyclingandenduranceshuttlewalkinginchronicobstructivepulmonarydisease